Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMARCA2 | P51531 | 9/20 | 0.66 |
| ▸ | SMARCA4 | P51532 | 8/20 | 0.66 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.60 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.60 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.60 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.60 |
| ▸ | JAK2 | O60674 | 1/20 | 0.57 |
| ▸ | JAK1 | P23458 | 1/20 | 0.57 |
| ▸ | TYK2 | P29597 | 1/20 | 0.57 |
| ▸ | ANO1 | Q5XXA6 | 1/20 | 0.44 |
| ▸ | AR | P10275 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10502486 | 0.88 | SMARCA2 (0.62) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL9599510 | 0.85 | SMARCA2 (0.59) | SMARCA2SMARCA4 | |
| SCHEMBL9599834 | 0.85 | SMARCA2 (0.86) | SMARCA2SMARCA4MEN1KMT2A | |
| SCHEMBL10560427 | 0.84 | SMARCA2 (0.61) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL9600748 | 0.83 | SMARCA2 (0.63) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL22125117 | 0.82 | SMARCA2 (0.67) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL11047044 | 0.81 | SMARCA2 (0.65) | SMARCA2SMARCA4MEN1KMT2A | |
| SCHEMBL3324675 | 0.81 | SMARCA2 (0.64) | SMARCA2SMARCA4AR | |
| SCHEMBL10561825 | 0.81 | SMARCA2 (0.61) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 | |
| SCHEMBL9599296 | 0.80 | SMARCA2 (0.59) | SMARCA2SMARCA4PIK3CAMAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2114941-B1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LTD (GB) | 2015-03-25 | — | — | EP | disclosed |
| US-8895745-B2 | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2014-11-25 | — | — | US | disclosed |
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | ASTEX THERAPEUTICS LIMITED (GB) | 2010-05-13 | — | — | US | disclosed |
| CN-101679408-A | Bicyclic heterocyclic compounds as FGFR inhibitors | ASTEX THERAPEUTICS LTD | 2010-03-24 | — | — | CN | disclosed |
| EP-2114941-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | Astex Therapeutics Limited (GB) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008078091-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS AS FGFR INHIBITORS | ASTEX THERAPEUTICS LIMITED (GB) | 2008-07-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100120761-A1 | Bicyclic Heterocyclic Compounds as FGFR Inhibitors | FGFR3, FGFR1, FGFR2 | SMARCA2 3174/4885SMARCA4 2870/4885PIK3CA 67/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.